Therefore, we suggested that Phaseol may reduce inflammatory cell activation and inflammatory response by acting on CXCL8 and IL2RA, thereby reducing tissue damage from excessive inflammatory response and alleviating the clinical symptoms of COVID-19. The gene discussed is CXCL8; the disease is COVID-19.